Chronic hepatitis B: early viral suppression and long‐term outcomes of therapy with oral nucleos(t)ides
暂无分享,去创建一个
[1] Huy Trinh,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.
[2] E. Schiff,et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[3] M. Tong,et al. Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States , 2008, Hepatology.
[4] R. Colonno,et al. Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance , 2008 .
[5] H. Tillmann,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.
[6] S. Locarnini. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure , 2008, Hepatology international.
[7] P. Marcellin,et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. , 2007, Annals of internal medicine.
[8] M. Yuen,et al. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5‐year ideal response , 2007, Hepatology.
[9] E. Keeffe,et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] A. Perelson,et al. Impact of Early Viral Kinetics on T-Cell Reactivity during Antiviral Therapy in Chronic Hepatitis B , 2007, Antiviral therapy.
[11] J. Sung,et al. Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B , 2007, Alimentary pharmacology & therapeutics.
[12] A. Lok,et al. Navigating the maze of hepatitis B treatments. , 2007, Gastroenterology.
[13] E. Keeffe,et al. New and emerging treatment of chronic hepatitis B. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[14] Y. Liaw,et al. Chronic hepatitis B: treatment alert , 2006 .
[15] George Kitis,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.
[16] Sheng-Nan Lu,et al. Virological Response and Incidence of Adefovir Resistance in Lamivudine-Resistant Patients Treated with Adefovir Dipivoxil , 2005, Antiviral therapy.
[17] Y. Liaw,et al. 51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients , 2006 .
[18] Chien-Jen Chen,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.
[19] A. Lok,et al. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005 , 2006, Hepatology.
[20] Guan-Tarn Huang,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.
[21] P. Marcellin,et al. A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 results , 2006 .
[22] Graeme Currie,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.
[23] J. Rodés,et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. , 2005, Journal of hepatology.
[24] S. Pol. [Epidemiology and natural history of hepatitis B]. , 2005, La Revue du praticien.
[25] E. Keeffe,et al. Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.
[26] D. Lavanchy,et al. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.
[27] P. Marcellin,et al. Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy , 2004, Journal of viral hepatitis.
[28] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.
[29] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.
[30] E. Jury. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003 .
[31] A. Lok,et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003, Journal of hepatology.
[32] J. Petersen,et al. Correlation of hepatitis B virus load with loss of e antigen and emerging drug‐resistant variants during lamivudine therapy , 2001, Journal of medical virology.
[33] M. Yuen,et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.
[34] H. Kumada,et al. [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.